Cargando…

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

OBJECTIVE: To examine the effects of disease activity, disability, and disease-modifying therapies (DMTs) on serum neurofilament light (NFL) and the correlation between NFL concentrations in serum and CSF in multiple sclerosis (MS). METHODS: NFL concentrations were measured in paired serum and CSF s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Novakova, Lenka, Zetterberg, Henrik, Sundström, Peter, Axelsson, Markus, Khademi, Mohsen, Gunnarsson, Martin, Malmeström, Clas, Svenningsson, Anders, Olsson, Tomas, Piehl, Fredrik, Blennow, Kaj, Lycke, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705244/ https://www.ncbi.nlm.nih.gov/pubmed/29079686 http://dx.doi.org/10.1212/WNL.0000000000004683

Ejemplares similares

Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing–remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023)

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab
por: Johnsson, Magnus, et al.
Publicado: (2022)

Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2022)

Inflammation-related plasma and CSF biomarkers for multiple sclerosis
por: Huang, Jesse, et al.
Publicado: (2020)

Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis
por: Sandelius, Åsa, et al.
Publicado: (2019)

Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study
por: Rosenstein, Igal, et al.
Publicado: (2021)

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
por: Salzer, Jonatan, et al.
Publicado: (2016)

A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis
por: Sandgren, Sofia, et al.
Publicado: (2023)

Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers
por: Novakova, Lenka, et al.
Publicado: (2018)

High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis
por: Singh, Avadhesh Kumar, et al.
Publicado: (2017)

The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey
por: Sandgren, Sofia, et al.
Publicado: (2023)

High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023)

Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
por: Manouchehrinia, Ali, et al.
Publicado: (2020)

Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
por: Bergman, Joakim, et al.
Publicado: (2016)

MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS)
por: Jernås, Margareta, et al.
Publicado: (2013)

Blood neurofilament light levels segregate treatment effects in multiple sclerosis
por: Delcoigne, Bénédicte, et al.
Publicado: (2020)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Neurofilament light and tau as blood biomarkers for sports-related concussion
por: Shahim, Pashtun, et al.
Publicado: (2018)

Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis
por: Håkansson, Irene, et al.
Publicado: (2018)

Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
por: Zhukovsky, Christina, et al.
Publicado: (2021)

CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1
por: Wasling, Pontus, et al.
Publicado: (2019)

Demographic and disease‐related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis
por: Zondra Revendova, Kamila, et al.
Publicado: (2022)

SARS‐COV‐2 a trigger of myelin oligodendrocyte glycoprotein‐associated disorder
por: Johnsson, Magnus, et al.
Publicado: (2022)

No change in plasma tau and serum neurofilament light concentrations in adolescent athletes following sport-related concussion
por: Wallace, Colin, et al.
Publicado: (2018)

Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre‐analytical conditions
por: Simrén, Joel, et al.
Publicado: (2021)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
por: Raket, Lars Lau, et al.
Publicado: (2020)

Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus
por: Tyrberg, Tobias, et al.
Publicado: (2020)

Plasma neurofilament light chain concentration in the inherited peripheral neuropathies
por: Sandelius, Åsa, et al.
Publicado: (2018)

Elevated plasma neurofilament light in aging reflects brain white‐matter alterations but does not predict cognitive decline or Alzheimer's disease
por: Nyberg, Lars, et al.
Publicado: (2020)

Neurogranin and Neurofilament Light Chain as Preclinical Biomarkers in Scrapie
por: Betancor, Marina, et al.
Publicado: (2022)

Neurofilament light chain in the vitreous humor of the eye
por: Subramanian, Manju L., et al.
Publicado: (2020)

Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers
por: Khademi, Mohsen, et al.
Publicado: (2013)

Increased CSF Levels of Phosphorylated Neurofilament Heavy Protein following Bout in Amateur Boxers
por: Neselius, Sanna, et al.
Publicado: (2013)

Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination
por: Al Nimer, Faiez, et al.
Publicado: (2016)

CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers
por: Rostgaard, Nina, et al.
Publicado: (2018)

Neurofilament light in blood – What more is needed for clinical implementation in multiple sclerosis?
por: Zetterberg, Henrik
Publicado: (2020)

Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies
por: Kmezic, Ivan, et al.
Publicado: (2022)

Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma
por: Sveijer, Malin, et al.
Publicado: (2022)

Confounding effect of blood volume and body mass index on blood neurofilament light chain levels
por: Manouchehrinia, Ali, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2jntugpjcvki5mbsncb0jmdp67